TipRanks
Go Ultimate55% OFF

Curis (CRIS) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Zanubrutinib, EmavusertibChronic Lymphocytic Leukemia, B-Cell MalignanciesPhase IINot Yet RecruitingA Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesNov 26, 2025―
Venetoclax, EmavusertibMyelodysplastic Syndrome, Acute Myelogenous Leukemiaphase1AndPhase2RecruitingDose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)Feb 10, 2020
Ibrutinib, EmavusertibRelapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphomaphase1AndPhase2RecruitingCA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Oct 17, 2017

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Curis Inc. (CRIS) have in its pipeline
Curis CRIS is currently developing the following drugs: Zanubrutinib, Emavusertib, Venetoclax, Emavusertib, Ibrutinib, Emavusertib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.